Insmed | INSM - Net Income


Insmed reported $-328.48M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Novartis USD 3.93B 113M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025